文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

温阳败毒饮对脓毒症(阳虚浊毒证)患者早期微循环障碍的影响:一项随机对照试验

[Effect of Wenyang Baidu Yin on early microcirculation disturbance in patients with sepsis (syndrome of Yang deficiency and turbid toxin): a randomized controlled trial].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2024-01-01
一句话结论在常规西药治疗基础上加用温阳败毒饮可改善脓毒症(阳虚浊毒证)患者24–48小时的乳酸、灌注指数等微循环指标及72小时SOFA评分。

本研究纳入2022年1月至2023年7月山西省中西医结合医院ICU收治的64例脓毒症(阳虚浊毒证)患者,随机数字表法分为对照组和观察组各32例。对照组接受常规西药治疗,观察组在常规西药治疗基础上加用温阳败毒饮200 mL/d(每次100 mL,间隔12小时)口服或鼻饲,连续3天。结果显示两组治疗后微循环指标均较治疗前改善,观察组治疗24小时和48小时乳酸和灌注指数改善更明显,治疗48小时毛细血管再充盈时间和皮肤花斑评分改善更明显,而中心静脉血氧饱和度和中心静脉-动脉血二氧化碳分压差各时间点组间无统计学显著差异;观察组治疗72小时APACHE II评分、SOFA评分和中医证候积分改善程度均显著高于对照组。结论认为在常规西药治疗基础上联用温阳败毒饮可在一定程度上显著改善脓毒症(阳虚浊毒证)患者的微循环障碍,从而改善预后。

要点

  • 观察组在常规西药治疗基础上加用温阳败毒饮200 mL/d(每次100 mL,间隔12小时)口服或鼻饲,连续3天。
  • 治疗24小时乳酸:观察组2.45±0.92 mmol/L vs 对照组3.07±1.07 mmol/L;治疗48小时:2.06±0.87 mmol/L vs 2.59±1.01 mmol/L,均P<0.05。
  • 治疗24小时灌注指数:观察组3.45±0.89 vs 对照组2.92±0.98;治疗48小时:3.56±0.99 vs 3.01±0.87,均P<0.05。
  • 治疗48小时毛细血管再充盈时间:观察组2.04±1.08 s vs 对照组2.62±0.99 s;皮肤花斑评分:观察组0.5(0.0, 1.0)vs 对照组1.0(1.0, 1.0),均P<0.05。
  • 治疗72小时SOFA评分:观察组6.0(6.0, 8.0)vs 对照组10.0(8.0, 13.0);APACHE II评分:观察组15.0(12.2, 16.0)vs 对照组17.0(13.5, 20.0);中医证候积分:观察组10.13±3.73 vs 对照组14.63±5.55,均P<0.05。

适用人群与场景

  • 2022年1月至2023年7月山西省中西医结合医院ICU收治的脓毒症(阳虚浊毒证)患者64例,随机数字表法分为对照组和观察组各32例。
  • 纳入标准:脓毒症(阳虚浊毒证)患者;排除标准:原文未报告。

处置流程与药物剂量

  • 对照组:常规西药治疗。
  • 观察组:在常规西药治疗基础上加用温阳败毒饮200 mL/d(每次100 mL,间隔12小时)口服或鼻饲,连续3天。
  • 监测时点:治疗前及治疗6、12、24、48小时检测ScvO2、Pcv-aCO2、乳酸、灌注指数、毛细血管再充盈时间、皮肤花斑评分;治疗前及治疗72小时记录中医证候积分;治疗前及治疗24、72小时记录SOFA和APACHE评分。

研究设计与关键结果

  • 研究类型:随机对照试验;样本量64例(对照组32例、观察组32例);单中心(山西省中西医结合医院ICU);人群为脓毒症(阳虚浊毒证)患者。
  • 两组性别、年龄及治疗前各微循环指标比较差异无统计学意义,基线一致。
  • 两组治疗后ScvO2、Pcv-aCO2、乳酸、灌注指数、毛细血管再充盈时间、皮肤花斑评分均较治疗前显著改善。
  • 治疗24小时和48小时乳酸:观察组2.45±0.92 mmol/L vs 对照组3.07±1.07 mmol/L(24小时),2.06±0.87 mmol/L vs 2.59±1.01 mmol/L(48小时);灌注指数:观察组3.45±0.89 vs 对照组2.92±0.98(24小时),3.56±0.99 vs 3.01±0.87(48小时),均P<0.05,观察组改善更明显。
  • 治疗48小时毛细血管再充盈时间:观察组2.04±1.08 s vs 对照组2.62±0.99 s;皮肤花斑评分:观察组0.5(0.0, 1.0)vs 对照组1.0(1.0, 1.0),均P<0.05,观察组改善更明显。
  • ScvO2和Pcv-aCO2各时间点组间差异均无统计学意义。
  • 治疗72小时APACHE II评分:观察组15.0(12.2, 16.0)vs 对照组17.0(13.5, 20.0);SOFA评分:观察组6.0(6.0, 8.0)vs 对照组10.0(8.0, 13.0);中医证候积分:观察组10.13±3.73 vs 对照组14.63±5.55,均P<0.05,观察组改善程度显著高于对照组。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在常规西药治疗基础上联用温阳败毒饮可在一定程度上显著改善脓毒症(阳虚浊毒证)患者的微循环障碍,从而改善预后。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To observe the effect of Wenyang Baidu Yin on early microcirculation indicators in patients with sepsis (syndrome of Yang deficiency and turbid toxin), analyze the specific therapeutic effect, and provide a new perspective for clinical treatment of microcirculation disorders in sepsis.

METHODS: Sixty-four patients with sepsis admitted to the intensive care unit (ICU) of Shanxi Province Hospital of Integrated Traditional Chinese and Western Medicine from January 2022 to July 2023 were enrolled. Patients were divided into control group and observation group by randomly number table method, with 32 cases in each group. The control group received conventional Western medicine treatment. On the basis of conventional Western medicine treatment, the observation group was given Wenyang Baidu Yin 200 mL/d (100 mL each time, with an interval of 12 hours) orally or by nasal feeding for 3 consecutive days. The central venous oxygen saturation (ScvO2), difference of central venous-to-arterial partial pressure of carbon dioxide (Pcv-aCO2), arterial lactic acid (Lac), pulse perfusion index (PI), capillary refill time (CRT), and skin mottling score (SMS) of two groups were detected before treatment and at 6, 12, 24, and 48 hours of treatment; simultaneously record the traditional Chinese medicine (TCM) syndrome score before treatment and at 72 hours of treatment, as well as the sequential organ failure assessment (SOFA) and acute physiology and chronic health evaluation (APACHE) before treatment and at 24 hours and 72 hours of treatment.

RESULTS: There were no statistically significant differences in gender, age, and various microcirculation indicators before treatment between the two groups, indicating consistent baseline characteristics. Compared with before treatment, the microcirculation indicators ScvO2, Pcv-aCO2, Lac, PI, CRT, and SMS in both groups showed significant improvement after treatment. Moreover, the observation group showed more significant improvements in Lac and PI compared to the control group at 24 hours and 48 hours of treatment [Lac (mmol/L): 2.45±0.92 vs. 3.07±1.07 at 24 hours, 2.06±0.87 vs. 2.59±1.01 at 48 hours; PI: 3.45±0.89 vs. 2.92±0.98 at 24 hours, 3.56±0.99 vs. 3.01±0.87 at 48 hours, all P < 0.05]. CRT and SMS showed more significant improvements compared to the control group at 48 hours of treatment [CRT (s): 2.04±1.08 vs. 2.62±0.99, SMS: 0.5 (0.0, 1.0) vs. 1.0 (1.0, 1.0), both P < 0.05], while there were no statistically significant differences in ScvO2 and Pcv-aCO2 at each time point between the two groups. After treatment, the APACHE score, SOFA score, and TCM syndrome score improved in both groups compared to before treatment, and the improvement degree of each score in the observation group was significantly higher than that in the control group [72 hours APACHE II score: 15.0 (12.2, 16.0) vs. 17.0 (13.5, 20.0), 72 hours SOFA score: 6.0 (6.0, 8.0) vs. 10.0 (8.0, 13.0), 72 hours TCM syndrome score: 10.13±3.73 vs. 14.63±5.55, all P < 0.05].

CONCLUSIONS: On the basis of conventional Western medicine treatment, the combination of Wenyang Baidu Yin can significantly improve microcirculation disorders in patients with sepsis (syndrome of Yang deficiency and turbid toxin) to a certain extent, thereby improving patient prognosis.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Liang J, Zhang J, Zhang S, et al. [Effect of Wenyang Baidu Yin on early microcirculation disturbance in patients with sepsis (syndrome of Yang deficiency and turbid toxin): a randomized controlled trial]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 39238402. doi:10.3760/cma.j.cn121430-20231120-00996

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。